Aporowicz Michal, Czopnik Piotr, Kubicka Eliza, Piotrowska Aleksandra, Dziegiel Piotr, Bolanowski Marek, Domoslawski Pawel
Department and Division of Surgical Didactics, Wroclaw Medical University, Wroclaw, Poland
Department of General, Minimally Invasive and Endocrine Surgery, Wroclaw Medical University, Wroclaw, Poland.
Anticancer Res. 2019 Mar;39(3):1151-1159. doi: 10.21873/anticanres.13224.
BACKGROUND/AIM: Morphological features, combined with Ki-67 proliferative index, remain the standard for discriminating benign and malignant adrenocortical tumors. The aim of this study was to evaluate the role of minichromosome maintenance proteins MCM-3, MCM-5, MCM-7, and Ki-67 as proliferative markers in adrenocortical tumors.
Specimens of 81 adrenocortical adenomas and 3 adrenocortical carcinomas were stained with antibodies against MCM-3, 5, 7 and Ki-67.
Malignant tumors were characterized by a greater size (p=0.017), volume (p=0.017), and higher levels of Ki-67 (p=0.005), MCM-3 (p=0.005), MCM-7 (p=0.008), but not MCM-5 (p=0.069). The markers' levels were independent from the tumors' size and volume, the patient's age and hormonal status. ROC curves showed Ki-67 (AUC 0.984), MCM-3 (AUC 0.984), and MCM-7 (AUC 0.950), but not MCM-5 (AUC 0.820) to be reliable markers.
Ki-67, MCM-3, and MCM-7, but not MCM-5 are reliable proliferative and diagnostic markers in discerning benign and malignant adrenocortical tumors.
背景/目的:形态学特征结合Ki-67增殖指数仍是鉴别肾上腺皮质肿瘤良恶性的标准。本研究旨在评估微小染色体维持蛋白MCM-3、MCM-5、MCM-7和Ki-67作为肾上腺皮质肿瘤增殖标志物的作用。
用抗MCM-3、5、7和Ki-67抗体对81例肾上腺皮质腺瘤和3例肾上腺皮质癌标本进行染色。
恶性肿瘤的特征为更大的尺寸(p=0.017)、体积(p=0.017)以及更高水平 的Ki-67(p=0.005)、MCM-3(p=0.005)、MCM-7(p=0.008),但MCM-5水平无差异(p=0.069)。这些标志物的水平与肿瘤的大小、体积、患者年龄及激素状态无关。ROC曲线显示Ki-67(曲线下面积0.984)、MCM-3(曲线下面积0.984)和MCM-7(曲线下面积0.950)是可靠的标志物,而MCM-5不是(曲线下面积0.820)。
在鉴别肾上腺皮质肿瘤的良恶性方面,Ki-67、MCM-3和MCM-7是可靠的增殖和诊断标志物,而MCM-5不是。